A 2025 Phase I trial (Lee & Burgess, 2025) demonstrated that IV BPC-157 doses up to 20 mg were tolerated in healthy volunteers with no serious adverse events
Dawn Ericsson, AgeRejuvenation's Chief Medical Officer, leads protocol design across all five Florida locations
All under $1 per serving with 1518g protein
Jubbonti will go up against Amgens Prolia for the treatment of osteoporotic men and postmenopausal women who are at high risk of fracture, while Wyost will challenge Amgens Xgeva in the prevention of skeletal-related events in patients with multiple myeloma and solid tumors with bone metastases, among other indications
Most people (including those with PCOS) dont have withdrawal syndrome when they discontinue metformin
As the provision of individualized care moves center stage in diabetes management, lixisenatide with once-daily dosing, a single maintenance dose and fixed-dose pens offers an important treatment option for type 2 diabetes